Becker Muscular Dystrophy (BMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Becker muscular dystrophy (BMD) is an X-linked recessive allelic muscular dystrophy caused by mutations in the DMD gene. BMD is characterised by less severe clinical phenotypes than DMD, with onset mostly during school age, between 5-15 years old, even though there are several reported cases of late-onset BMD in the third and fourth decades of life. BMD clinical phenotypes are varied, ranging from mild symptoms, such as muscle cramps, myalgia, myoglobinuria and mild myopathy, to severe myopathy that can interfere with patient's ability to walk. Cardiac involvement has been reported in 70% of BMD cases. The most common type of cardiac abnormality is dilated cardiomyopathy, which is associated with congestive heart failure and premature death.
·
The incidence of Becker muscular dystrophy
(BMD) has been estimated to be between 1 in 18,000 and 1 in 30,000 male births.
·
The prevalence of BMD is estimated to be 17 to
27 cases per million people. Female carriers of X-linked recessive conditions
have a 50% (1 in 2) risk of passing the mutated gene to each child. Male
children have a 50% risk of being affected, and female children have a 50% risk
of being a carrier.
Thelansis’s
“Becker Muscular Dystrophy (BMD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Becker
Muscular Dystrophy (BMD) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Becker Muscular
Dystrophy (BMD) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Becker
Muscular Dystrophy (BMD) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment